Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Irinotecan

Paclitaxel

Vaccines

Gemcitabine

Leucovorin

Fluorouracil

Levoleucovorin

Albumin-Bound Paclitaxel

Oxaliplatin

Folic Acid

Folfirinox

Folinic Acid

Folate

Vitamin B9

Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.

Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.

4 doses of DC vaccine at 2 weeks interval, combined with either:

* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)
* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation
* Gemcitabine + nab-paclitaxel

The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .

The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.

Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL.

DC Vaccine + Standard of Care Chemotherapy

Carlos Becerra, MD

The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU) (FOLFIRINOX) and nab-paclitaxel/gemcitabine in patients with pancreatic cancer.

The secondary objectives of this trial are to determine preliminary clinical efficacy based on response rates, overall survival and progression free survival compared with historic control, and surgical conversion rate as defined as percent of locally advanced (unresectable) patients achieving resectability within 6 months of treatment initiation. Also, to identify vaccine immunogenicity by measuring acquired, T cell-mediated immune activating events post-vaccination and to correlate clinical response with acquired immune responses.

This is a single center, exploratory pilot safety, open label, phase I trial that will evaluate the combination of DC vaccination in 2 groups of patients when combined with chemotherapy including FOLFIRINOX and gemcitabine+nab-paclitaxel in patients with pancreatic cancer. The investigations will accrue 20 evaluable subjects over 20 months with 10 patients in each group. Subjects will be assigned to group 1 or group 2 according to the subject's disease stage.

The protocol will be conducted in two stages:

The 1st 3 patients will be enrolled to either group to receive DC vaccinations combined with standard chemotherapy. A safety analysis will be performed after the first 3 patients have completed 6 vaccines. If no vaccine dose-limiting toxicity occurs in any of the 3 patients then the study will proceed with stage 2. Stage 2 will include the enrollment of the remaining 17 patients.

Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer

A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer

Follow up for toxicity will be recorded for the first 30 days following the last DC vaccination and any long-term toxicity will be followed for 3 years after completing study therapy.

Overall response rate will be assessed by using standard Response Evaluation Criteria in Solid Tumors (RECIST).

Time from the start of therapy to death from any cause.

Time from enrollment until objective tumor progression or death

Quality of Life score will be assessed by using self-administered questionnaires

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer	NCT02548169	Pancreatic Canc...	DC Vaccine + St...	18 Years -	Baylor Research Institute
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer	NCT02548169	Pancreatic Canc...	DC Vaccine + St...	18 Years -	Baylor Research Institute

Spots Global Cancer Trial Database for dc vaccine + standard of care chemotherapy